<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of herpes zoster
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of herpes zoster
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of herpes zoster
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mary A Albrecht, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Myron J Levin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin S Hirsch, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth E Schmader, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer Mitty, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 29, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Varicella-zoster virus (VZV) infection causes two diseases. Primary infection with VZV results in varicella, also known as chickenpox, characterized by vesicular lesions on an erythematous base in different stages of development on the face, trunk, and extremities. During varicella, VZV establishes a latent infection in sensory ganglia.
        </p>
        <p>
         Herpes zoster, also known as shingles, results from activation of latent VZV from a sensory ganglion. The virus then travels down the associated sensory nerve to the skin, leading to a characteristic dermatomal rash, usually in association with dermatomal pain. Although herpes zoster can occur at any age, it is more commonly a disease of adults &gt;50 years of age. In addition, the severity and complications of herpes zoster are much more common in this age group.
        </p>
        <p>
         The treatment of herpes zoster will be reviewed here. The epidemiology, clinical manifestations, diagnosis, and prevention of herpes zoster are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes zoster"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8331.html" rel="external">
          "Varicella-zoster virus infection in pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8343.html" rel="external">
          "Vaccination for the prevention of shingles (herpes zoster)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4047.html" rel="external">
          "Prevention and control of varicella-zoster virus in hospitals"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2643063430">
         <span class="h1">
          DETERMINING EXTENT OF INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with herpes zoster present with a dermatomal vesicular rash and acute neuritis; acute neuritis commonly precedes ("prodromal pain") the rash by one to three days. (See
         <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Common findings'
         </a>
         .)
        </p>
        <p>
         During the initial evaluation of a patient with herpes zoster, it is important to exclude signs and symptoms of complicated zoster. This includes disseminated disease or involvement of the eye, ear, or central nervous system  (
         <a class="graphic graphic_table graphicRef143354" href="/z/d/graphic/143354.html" rel="external">
          table 1
         </a>
         ). As an example, if cutaneous lesions are present on the tip or side of the nose, patients are at risk for herpes zoster ophthalmicus. Such patients should be evaluated for any signs or symptoms of eye involvement (eg, tearing, ocular pain, blurred vision, conjunctival injection, swelling/erythema of the lid and periorbital structures); if these clinical features are present, the patient should be evaluated by an ophthalmologist. (See
         <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Complications'
         </a>
         and
         <a class="local">
          'Ocular disease'
         </a>
         below.)
        </p>
        <p>
         It is also important to rule out other etiologies that cause similar syndromes, such as herpes simplex virus infection. (See
         <a class="medical medical_review" href="/z/d/html/8347.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8334.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2809420933">
         <span class="h1">
          UNCOMPLICATED DERMATOMAL RASH
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with uncomplicated dermatomal zoster, the rash is usually limited to one dermatome, although contiguous dermatomes can be involved. (See
         <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes zoster"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3841947215">
         <span class="h2">
          Antiviral therapy
         </span>
        </p>
        <p class="headingAnchor" id="H3248058458">
         <span class="h3">
          Goals of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of uncomplicated herpes zoster includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antiviral therapy to hasten healing of cutaneous lesions, decrease the duration and severity of acute neuritis, and prevent new lesion formation [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="local">
          'Antiviral therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Analgesia for patients with moderate to severe acute neuritis. (See
         <a class="local">
          'Management of acute neuritis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Several lines of evidence suggest that antiviral therapy hastens resolution of cutaneous lesions and the pain of herpes zoster [
         <a href="#rid3">
          3-5
         </a>
         ]. Antiviral therapy likely decreases viral shedding and may reduce the risk of transmission of varicella-zoster virus (VZV).
        </p>
        <p>
         However, it is unclear if antiviral therapy prevents postherpetic neuralgia (PHN) because of conflicting study results, which are due in part to different methodologies of pain assessment, definitions of PHN, and length of follow-up [
         <a href="#rid3">
          3-6
         </a>
         ]. The treatment of established PHN is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5289.html" rel="external">
          "Postherpetic neuralgia", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1874422922">
         <span class="h3">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The indications for treatment depend upon duration of symptoms and the presence or absence of comorbid conditions.
        </p>
        <p class="headingAnchor" id="H2089410675">
         <span class="h4">
          Patients who present within 72 hours of onset
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend antiviral therapy for all patients with herpes zoster who present within 72 hours of clinical signs and symptoms  (
         <a class="graphic graphic_algorithm graphicRef143355" href="/z/d/graphic/143355.html" rel="external">
          algorithm 1
         </a>
         ). Antiviral therapy should be initiated as soon as possible to maximize the potential benefits of treatment. (See
         <a class="local">
          'Regimen selection'
         </a>
         below.)
        </p>
        <p>
         The benefit of antiviral therapy appears to be greatest in patients older than 50 years of age, in whom the pain of herpes zoster is generally greater and persists longer and in whom complications of herpes zoster are more likely [
         <a href="#rid3">
          3,7
         </a>
         ]. Although the efficacy of antiviral therapy in immune-competent patients less than 50 years of age has not been as well studied, the risk of adverse events secondary to antiviral therapy is very low. Efficacy has been demonstrated in younger patients who are immune compromised.
        </p>
        <p>
         More detailed information on the efficacy of antiviral therapy is found below. (See
         <a class="local">
          'Approach for most patients'
         </a>
         below and
         <a class="local">
          'Immunocompromised patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H972408913">
         <span class="h4">
          Selected patients who present after 72 hours
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest antiviral therapy in certain patients with herpes zoster even if &gt;72 hours have passed  (
         <a class="graphic graphic_algorithm graphicRef143355" href="/z/d/graphic/143355.html" rel="external">
          algorithm 1
         </a>
         ). This primarily includes persons who have, or are likely to have, an impaired immune response to VZV infection. However, there is no benefit of antiviral therapy after all the lesions have crusted, regardless of the patient's underlying condition.
        </p>
        <p>
         These patients include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunocompromised persons
         </strong>
         – We administer antiviral therapy to immunocompromised patients who present after 72 hours of symptoms, particularly those at risk for disseminated disease. This includes hematopoietic cell transplant or solid organ transplant recipients, persons with hematologic malignancies, those with solid tumor malignancies receiving chemotherapy, persons with advanced HIV infection (eg. CD4 count &lt;200 cells/microL, especially those not receiving antiretroviral therapy), persons receiving high-dose glucocorticoids (eg, &gt;20 mg/day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         for more than two weeks) or immunomodulatory therapy (eg,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         or TNF inhibitors) [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Selected immunocompetent persons
         </strong>
         – We treat certain immunocompetent persons, even if they present after 72 hours. These include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with lesions at a site associated with an increased risk of complications. As an example, patients with involvement of the V1 dermatome are at increased risk of future ocular involvement even if they do not have overt ocular involvement at presentation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients who have advanced age (eg, &gt;65) or those who are forming new crops of lesions after 72 hours. These groups of patients likely have decreased immunity to VZV [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Although the utility of initiating antiviral therapy more than 72 hours after the onset of lesions in such persons is unknown since clinical trials did not evaluate the efficacy of treatment initiated beyond this time period [
         <a href="#rid3">
          3
         </a>
         ], treatment may be of some benefit.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3745118762">
         <span class="h3">
          Regimen selection
         </span>
        </p>
        <p class="headingAnchor" id="H253256926">
         <span class="h4">
          Approach for most patients
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of agent
         </strong>
         – The nucleoside analogues
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         , and
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          famciclovir
         </a>
         are the preferred antivirals for treatment of herpes zoster  (
         <a class="graphic graphic_algorithm graphicRef143355" href="/z/d/graphic/143355.html" rel="external">
          algorithm 1
         </a>
         ). For most patients, oral therapy is sufficient. Intravenous treatment is reserved for patients who have complications of herpes zoster (eg, acute retinal necrosis, encephalitis) or severe immune compromise. (See
         <a class="local">
          'Complicated zoster'
         </a>
         below and
         <a class="local">
          'Immunocompromised patients'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Of the available agents, we generally prefer
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         or
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          famciclovir
         </a>
         given their superior bioavailability and the need for less frequent dosing compared with
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         , although small comparative trials do not support the efficacy of one over the other [
         <a href="#rid11">
          11-13
         </a>
         ]. However, acyclovir is often preferred in persons who are pregnant. (See
         <a class="local">
          'Pregnancy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Brivudine is another effective antiviral against VZV that is not available in the United States but is often used in other countries. It is a nucleoside analog that is mono-phosphorylated by a unique VZV-specified enzyme and changed into the triphosphate by cellular enzymes. Brivudine triphosphate is incorporated into VZV DNA and also is a competitive inhibitor of VZV DNA synthesis. However, the primary metabolic product of brivudine is bromovinyluracil, which inhibits enzymes degrading other fluoropyrimidines (eg, 5
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         and other bone marrow-suppressing chemotherapeutic drugs), and thus could be extremely toxic in certain clinical situations when these agents are used.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – The doses used for oral treatment of herpes zoster are:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          Valacyclovir
         </a>
         : 1000 mg three times daily
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          Famciclovir
         </a>
         : 500 mg three times daily
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          Acyclovir
         </a>
         : 800 mg five times daily
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The typical course of treatment is seven days. (See
         <a class="local">
          'Expected response to treatment'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          Acyclovir
         </a>
         and its analogues are dependent upon renal function for clearance, and dose adjustment is needed in moderate to severe renal insufficiency. Dosing information can be found in the Lexicomp drug information topics within UpToDate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The doses used to treat herpes zoster infection are higher than those typically required for herpes simplex virus since VZV is less sensitive to nucleoside analogs. However, these nucleoside analogs have well-established safety records at the currently recommended doses. Adverse events are uncommon, but when present typically include nausea, diarrhea, or headache. More detailed information about the individual agents is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">
          "Acyclovir: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8337.html" rel="external">
          "Valacyclovir: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8338.html" rel="external">
          "Famciclovir: An overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Data supporting the efficacy of these agents for the treatment of herpes zoster include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oral
         </strong>
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         – Oral acyclovir was the first nucleoside analogue available for the treatment of herpes simplex and herpes zoster. (See
         <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">
          "Acyclovir: An overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In a meta-analysis of four placebo-controlled trials involving 691 patients (mean age 62 years), those who received
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         (800 mg five times daily) administered within 48 to 72 hours of the onset of rash were more likely to have resolution of moderate/severe acute neuritis (hazard ratio [HR] 1.46; 95% CI 1.1-1.93) and PHN, defined as the presence of pain at three and six months after resolution of the rash (HR 1.8; 95% CI 1.35-2.43) [
         <a href="#rid3">
          3
         </a>
         ]. In a subsequent meta-analysis, which included one additional placebo-controlled trial, antiviral therapy decreased the risk of PHN (as defined by any pain at six months) by 46 percent [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          Valacyclovir
         </a>
         – The limited bioavailability of
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         necessitated frequent daily dosing (800 mg five times daily), prompting the development of a prodrug with improved absorption (valacyclovir). Valacyclovir is well absorbed from the gastrointestinal tract and rapidly converted to acyclovir in vivo, thereby providing a three- to fivefold increase in acyclovir bioavailability. This results in improved pharmacokinetics and less frequent dosing. (See
         <a class="medical medical_review" href="/z/d/html/8337.html" rel="external">
          "Valacyclovir: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8337.html" rel="external">
          "Valacyclovir: An overview", section on 'Basic pharmacokinetics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A randomized, double-blind trial compared
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         (1000 mg orally three times daily for 7 or 14 days) with
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         (800 mg orally five times daily for seven days) for treatment of herpes zoster in 1141 immunocompetent adults (mean age 68 years) [
         <a href="#rid14">
          14
         </a>
         ]. Cutaneous lesions resolved at similar rates in all treatment groups; however, valacyclovir for 7 or 14 days accelerated the resolution of acute neuritis compared with acyclovir (median duration of pain 38 and 44 days for the 7 and 14 day course of valacyclovir, respectively, compared with 51 days for acyclovir).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          Famciclovir
         </a>
         – Famciclovir, the prodrug of
         <a class="drug drug_general" data-topicid="9746" href="/z/d/drug information/9746.html" rel="external">
          penciclovir
         </a>
         , is well absorbed from the gastrointestinal tract and rapidly converted in the intestinal wall and liver to penciclovir, which has good activity against VZV [
         <a href="#rid7">
          7,15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8338.html" rel="external">
          "Famciclovir: An overview", section on 'Mechanism of action'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A placebo-controlled clinical trial was conducted in 419 immunocompetent adults (mean age 50 years) with uncomplicated zoster to evaluate the efficacy of standard-dose and high-dose
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          famciclovir
         </a>
         (500 or 750 mg three times daily) with placebo [
         <a href="#rid7">
          7
         </a>
         ]. All patients initiated therapy within 72 hours of rash onset and were treated for seven days. Famciclovir was associated with a modest improvement in lesion-healing rates compared with placebo (median five to six versus seven days). While there was no difference in the incidence of PHN among the three treatment arms, the use of famciclovir therapy, regardless of dose, conferred a selective reduction in the median duration of PHN compared with placebo (62 and 55 days with low- and high-dose famciclovir, respectively versus 119 days).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3043623361">
         <span class="h4">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We prefer oral
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         (800 mg five times daily) rather than other antiviral agents during pregnancy since there is the most experience with this medication in pregnancy. Although there are no clinical trials evaluating specific antiviral agents in pregnant women with herpes zoster, experience with acyclovir in both herpes simplex infection and varicella pneumonia, which is supported by a large registry of acyclovir exposure during pregnancy, suggests that this drug is safe in pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">
          "Acyclovir: An overview", section on 'Use in pregnancy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8331.html" rel="external">
          "Varicella-zoster virus infection in pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8340.html" rel="external">
          "Genital herpes simplex virus infection and pregnancy", section on 'Drug choice, dose, and safety'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H651874047">
         <span class="h4">
          Immunocompromised patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regimen selection in immunocompromised patients depends upon the degree of immunocompromise and the subsequent risk of dissemination.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients at high risk for dissemination
         </strong>
         – Intravenous (IV)
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         (10 mg/kg every eight hours) is used as initial therapy in patients who are at high risk for dissemination [
         <a href="#rid2">
          2
         </a>
         ]. This includes hematopoietic cell (HCT) or organ transplant recipients with significant immunosuppression (eg, HCT recipients in the pre- or post-transplant period, those with graft versus host disease, or cancer patients with leukopenia). Small clinical trials have found that IV acyclovir substantially reduces the risk for cutaneous and visceral dissemination in highly immunocompromised patients [
         <a href="#rid16">
          16-20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         After initial clinical improvement, patients may be switched to an oral agent with good bioavailability, such as
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         or
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          famciclovir
         </a>
         . Patients should be treated until all lesions have crusted (typically 7 to 14 days).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other immunocompromised patients
         </strong>
         – For other immunocompromised patients, oral therapy with
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         (1 g three times daily) can be used. In a randomized trial of 87 immunocompromised patients with clinical evidence of localized herpes zoster, patients who received this regimen had the same median time to full crusting of lesions as those who received valacyclovir 2 g three times daily [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2637137778">
         <span class="h3">
          Expected response to treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The expected response to treatment is for new vesicles to stop forming within five to seven days of therapy. (See
         <a class="local">
          'Regimen selection'
         </a>
         above.)
        </p>
        <p>
         If there is a delayed response to treatment, antiviral therapy treatment should be extended until new vesicle formation has ceased. In some cases, transition to intravenous
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         is appropriate (eg, immunocompromised patients with new vesicle formation despite several days of oral therapy).
        </p>
        <p>
         The patient should also be evaluated to ensure there are no complications associated with herpes zoster (eg, secondary bacterial infection). (See
         <a class="local">
          'Secondary bacterial infection'
         </a>
         below.)
        </p>
        <p>
         Patients with a delayed response to treatment generally have decreased immunity to VZV infection. Thus, when evaluating the patient, clinicians should assess for clinical manifestations that would suggest underlying immune suppression. We do not routinely do additional work-up to search for immunocompromising conditions unless the initial clinical evaluation is suggestive of a certain disease.
        </p>
        <p class="headingAnchor" id="H2522270064">
         <span class="h2">
          Limited role for adjunctive therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with uncomplicated zoster, we suggest against the routine use of adjunctive agents (eg,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         , tricyclic antidepressants, or glucocorticoids) in the acute setting. However, some of these agents may have a role in select patients with acute neuritis, as discussed below. (See
         <a class="local">
          'Management of acute neuritis'
         </a>
         below.)
        </p>
        <p>
         There are no definitive data to suggest these adjunctive agents prevent PHN from developing [
         <a href="#rid22">
          22
         </a>
         ], and the risk of adverse events can be increased by adjunctive agents in elderly patients. Although some early trials suggested glucocorticoids in addition to
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         made people feel better sooner [
         <a href="#rid23">
          23-27
         </a>
         ], a subsequent meta-analysis did not demonstrate any benefit of combination therapy on quality of life or the incidence of PHN [
         <a href="#rid24">
          24
         </a>
         ]. In addition, their role in hastening the resolution of the rash is unclear.
        </p>
        <p class="headingAnchor" id="H2429232122">
         <span class="h2">
          Assessing and managing pain
         </span>
        </p>
        <p class="headingAnchor" id="H3853664221">
         <span class="h3">
          Patient monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         After treatment for herpes zoster has been initiated, patients should be assessed for improvement in their clinical symptoms, including worsening or persisting pain. Serial patient monitoring should include standardized pain measures and frequent follow-up to assess efficacy in relief of symptoms [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Approximately 10 to 15 percent of patients may develop PHN, defined as pain (defined as severity of 3 out of 10) which interferes with daily activity that is present 90 days after the onset of rash (or begins after this interval) in the distribution of the documented episode of acute herpes zoster. This a more frequent problem in patients over the age of 60 years [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3913255119">
         <span class="h3">
          Management of acute neuritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although antiviral therapy reduces pain associated with acute neuritis, pain syndromes associated with herpes zoster can still be severe. Thus, certain interventions may be needed in addition to antiviral therapy.
        </p>
        <p>
         Management of acute neuritis must be individualized and requires the same principles as managing any pain: use of standardized pain measures, scheduled analgesia, and consistent and frequent monitoring to adjust dosing to the needs of the patient and to avoid side effects.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For all patients, nonsteroidal anti-inflammatory drugs and
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         can be useful agents to alleviate pain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those with severe pain, management is more difficult, and additional agents may be needed. The choice of treatment is based upon the patient's comorbidities, concurrent medications, pain intensity, and preferences.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Options include [
         <a href="#rid29">
          29
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Short-acting opioid analgesics
         </strong>
         – Short-acting opioid analgesics (eg,
         <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">
          oxycodone
         </a>
         ) are often the first option because of their efficacy in managing severe acute pain and evidence supporting their use in acute zoster neuritis [
         <a href="#rid22">
          22
         </a>
         ]. We use the lowest effective dose for the shortest duration possible because of associated side effects, especially in older patients. (See
         <a class="medical medical_review" href="/z/d/html/108806.html" rel="external">
          "Management of acute pain in opioid naïve adults in the ambulatory setting"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3017.html" rel="external">
          "Geriatric health maintenance"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Corticosteroids
         </strong>
         – If the patient has severe pain despite a short-acting opioid, a short course of corticosteroids may offer some benefit (eg, 10- to 14-day tapering course of oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         starting at 40 mg/day). Limited data suggest that corticosteroids in addition to
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         may improve overall well-being and/or improve acute pain [
         <a href="#rid23">
          23,25,30,31
         </a>
         ]. However, corticosteroids should generally be avoided in patients with certain comorbid conditions (eg, diabetes mellitus).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          Gabapentin
         </a>
         – Gabapentin may reduce acute pain in some patients [
         <a href="#rid22">
          22,32,33
         </a>
         ], although the evidence is mixed [
         <a href="#rid34">
          34-36
         </a>
         ]. By contrast, this agent is frequently used for management of post-herpetic neuralgia. (See
         <a class="medical medical_review" href="/z/d/html/5289.html" rel="external">
          "Postherpetic neuralgia", section on 'Gabapentinoids for most patients with moderate or severe pain'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with unrelenting pain, neural blockade with a long acting agent like
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         can also be considered [
         <a href="#rid29">
          29,37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2884665094">
         <span class="h3">
          Management of postherpetic neuralgia
         </span>
         <span class="headingEndMark">
          —
         </span>
         PHN (pain which interferes with daily activity that is present 90 days after the onset of rash in the distribution of the documented episode of acute herpes zoster) can be difficult to treat, and some patients require multimodal therapy for symptomatic management as well as referral to a pain management center, if available. The approach to treatment of PHN should be individualized according to severity and location of pain, comorbid conditions, medication side effect profile, treatment cost and availability, and patient values and preferences. This is discussed in detail in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/5289.html" rel="external">
          "Postherpetic neuralgia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3235951251">
         <span class="h2">
          Additional considerations
         </span>
        </p>
        <p class="headingAnchor" id="H3860831140">
         <span class="h3">
          Secondary bacterial infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although uncommon, secondary bacterial infections of the zoster rash can occur. Patients should be counseled to contact their clinician if they observe increased erythema, warmth, and/or purulence surrounding any lesions, which could suggest secondary bacterial skin infection.
        </p>
        <p>
         Should a bacterial infection be suspected at the time of the initial evaluation or during follow-up visits, the patient should receive appropriate antibiotic coverage in addition to antiviral therapy; regimens should include coverage for both staphylococcal and streptococcal species. (See
         <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">
          "Acute cellulitis and erysipelas in adults: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2972162528">
         <span class="h3">
          Treatment failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         On rare occasion, a patient may have persistence or progression of lesions on treatment. There is no standard approach to managing treatment failure. In this setting, the lesions should be cultured and the virus isolated should be sent for resistance testing. If drug resistant virus is present, alternative agents can be used (eg,
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         ). Such patients should be managed in conjunction with an infectious diseases specialist.
        </p>
        <p class="headingAnchor" id="H2797634178">
         <span class="h3">
          Recurrent zoster
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with recurrent zoster should be treated with antiviral therapy using the recommended dose and duration for treatment of an initial episode of herpes zoster. (See
         <a class="local">
          'Antiviral therapy'
         </a>
         above.)
        </p>
        <p>
         Since episodes of recurrent zoster are uncommon, it is important that clinicians assess the patient to determine the certainty of the diagnosis [
         <a href="#rid38">
          38-40
         </a>
         ]. A common error is to mistake recurrent herpes simplex for herpes zoster when the lesions are in the perioral or perigenital area, including the buttock. If the diagnosis is uncertain, confirmatory testing is warranted. (See
         <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Recurrent herpes zoster'
         </a>
         .)
        </p>
        <p>
         In addition, clinicians should assess patients with recurrent zoster for clinical features that would suggest underlying immune suppression. However, we do not routinely do additional work-up to search for immunocompromising conditions unless the initial clinical evaluation is suggestive of a certain disease.
        </p>
        <p class="headingAnchor" id="H1595824332">
         <span class="h1">
          COMPLICATED ZOSTER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain patients with herpes zoster will have ocular, otic, or neurologic manifestations. Such patients may require intravenous (IV) and/or prolonged therapy. In addition, there may be a role for adjunctive glucocorticoids in certain conditions.
        </p>
        <p class="headingAnchor" id="H3978780702">
         <span class="h2">
          Disseminated infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disseminated zoster includes extensive cutaneous involvement (eg, &gt;2 contiguous dermatomes, lesions involving both sides of the body or non-contiguous dermatomes), and/or visceral involvement  (
         <a class="graphic graphic_table graphicRef143354" href="/z/d/graphic/143354.html" rel="external">
          table 1
         </a>
         ). Disseminated zoster almost always occurs in those who are immunocompromised. (See
         <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Special considerations in immunocompromised hosts'
         </a>
         .)
        </p>
        <p>
         In such patients, IV
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         (10 mg/kg every eight hours) should be initiated. When lesions are improving the patient can be transitioned to oral treatment such as
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         (1 g three times daily). The duration of therapy is typically 10 to 14 days but may need to be extended in those with ongoing symptoms. The use of IV therapy is based upon early data that found IV acyclovir accelerates the rate of clearance of virus from vesicles, as compared with no therapy or therapy with vidarabine [
         <a href="#rid18">
          18,41
         </a>
         ]. Studies comparing oral therapy versus IV acyclovir for disseminated disease have not been conducted.
        </p>
        <p>
         Patients with disseminated infection are typically managed in the hospital setting. For such persons, appropriate infection control precautions (eg, standard, droplet, and airborne) should be implemented. (See
         <a class="medical medical_review" href="/z/d/html/4047.html" rel="external">
          "Prevention and control of varicella-zoster virus in hospitals", section on 'Infection control measures'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2865312991">
         <span class="h2">
          Ocular disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ocular manifestations of herpes zoster include herpes zoster ophthalmicus (HZO) and acute retinal necrosis (ARN). (See
         <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Herpes zoster ophthalmicus'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Acute retinal necrosis'
         </a>
         .)
        </p>
        <p>
         Patients with these conditions should be managed in conjunction with an ophthalmologist. Immediate treatment is required since they can be associated with loss of vision. Treatment includes antiviral therapy, and in some cases, additional therapies may be warranted (eg, corticosteroids for selected patients with HZO or intravitreal
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         for ARN) [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2997292345">
         <span class="h2">
          Ramsay Hunt syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major otologic complication of varicella-zoster virus (VZV) reactivation is the Ramsay Hunt syndrome, which typically includes the triad of ipsilateral facial paralysis, ear pain, and vesicles in the auditory canal and/or auricle. Other clinical manifestations may include tinnitus or nystagmus. (See
         <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Ramsay Hunt syndrome (herpes zoster oticus)'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients, we administer
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         (1 g three times per day) for 7 to 10 days
         <strong>
          and
         </strong>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (1 mg/kg for five days, without a taper).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In severe cases (eg, vertigo, tinnitus, or hearing loss), IV therapy can be initiated, and the patient can then be transitioned to an oral antiviral agent when the lesions begin to crust.
        </p>
        <p>
        </p>
        <p>
         There are few data to guide treatment decisions about management of this complication. Although a systematic review found no evidence that antiviral agents have a beneficial effect on outcomes in Ramsay Hunt syndrome [
         <a href="#rid44">
          44
         </a>
         ], a subsequent retrospective review of 101 patients found that patients who received
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         and glucocorticoids recovered significantly more than those who had only one or no pharmacologic treatment [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1703276533">
         <span class="h2">
          Neurologic complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         IV
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         (10 mg/kg IV every eight hours) should be administered to patients with neurologic complications where viral replication likely plays an important role (eg, symptomatic meningitis, encephalitis, and myelitis) [
         <a href="#rid2">
          2
         </a>
         ]. Treatment is generally administered for 10 to 14 days. This approach is supported by expert opinion. An additional discussion of the neurologic manifestations of VZV is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8271.html" rel="external">
          "Varicella zoster virus vasculopathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2518260582">
         <span class="h1">
          PREVENTING TRANSMISSION TO OTHERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with herpes zoster can transmit varicella-zoster virus (VZV) to individuals who have not had varicella and have not received the
         <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">
          varicella vaccine
         </a>
         . VZV is transmitted by direct contact or by aerosolization of virus from skin lesions. In general, VZV is much less transmissible from a person presenting with herpes zoster than from a person presenting with varicella (chickenpox). (See
         <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Transmission'
         </a>
         .)
        </p>
        <p>
         Patients with localized zoster (ie, a dermatomal rash) are not infectious before vesicles appear and are no longer infectious when the lesions have crusted. Patients should be counseled about the risk of viral transmission to others [
         <a href="#rid2">
          2
         </a>
         ]. In addition, until the rash has fully crusted, patients should be advised to:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Keep the rash covered to reduce the risk of spreading the virus to others.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoid contact with immunocompromised individuals as well as those who have never had chickenpox or the
         <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">
          varicella vaccine
         </a>
         [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         More detailed discussions of how to prevent transmission of VZV are found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4047.html" rel="external">
          "Prevention and control of varicella-zoster virus in hospitals"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8273.html" rel="external">
          "Post-exposure prophylaxis against varicella-zoster virus infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3555875158">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110219.html" rel="external">
          "Society guideline links: Varicella-zoster virus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15376.html" rel="external">
          "Patient education: Shingles (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/4023.html" rel="external">
          "Patient education: Shingles (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1675381383">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Uncomplicated dermatomal zoster
         </strong>
         – Uncomplicated herpes zoster typically presents with prodromal pain, a dermatomal vesicular rash, and dermatomal pain (acute neuritis). (See
         <a class="local">
          'Determining extent of infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Uncomplicated herpes zoster excludes patients with signs and symptoms of disseminated disease or involvement of the eye, ear, or central nervous system  (
         <a class="graphic graphic_table graphicRef143354" href="/z/d/graphic/143354.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Complicated zoster'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Indications for antiviral treatment
         </strong>
         – For patients with uncomplicated zoster, the benefit of antiviral treatment depends on the duration of symptoms and other factors  (
         <a class="graphic graphic_algorithm graphicRef143355" href="/z/d/graphic/143355.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Within 72 hours of symptom onset
         </strong>
         – For patients who present within 72 hours of symptom onset and have uncrusted lesions, we recommend antiviral therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Antivirals promote healing of skin lesions, lessen the severity and duration of acute neuritis, and reduce the incidence or severity of chronic pain (ie, postherpetic neuralgia). (See
         <a class="local">
          'Patients who present within 72 hours of onset'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Beyond 72 hours of symptom onset
         </strong>
         – For selected patients who present beyond 72 hours of symptoms and have uncrusted lesions, we also suggest antiviral therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). This includes: immunocompromised patients, patients with lesions in locations associated with complications (eg, V1 dermatome), patients age &gt;65 years, and patients forming new crops of lesions. (See
         <a class="local">
          'Selected patients who present after 72 hours'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         There is no benefit of antiviral therapy once all lesions have crusted.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antiviral therapy selection and duration: Immunocompetent patients
         </strong>
         – For most immunocompetent patients, we suggest oral
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         (1000 mg three times daily) or
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          famciclovir
         </a>
         (500 mg three times daily)  (
         <a class="graphic graphic_algorithm graphicRef143355" href="/z/d/graphic/143355.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). These agents are dosed less frequently than
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         (800 mg five times daily). (See
         <a class="local">
          'Approach for most patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For pregnant patients, we prefer oral
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         since there is the most experience with this medication in pregnancy and extensive safety experience. (See
         <a class="local">
          'Pregnancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         We continue treatment until new vesicle formation has ceased; the typical duration is seven days. For patients with delayed response to therapy, we assess for clinical manifestations that would suggest underlying immune compromise. (See
         <a class="local">
          'Expected response to treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antiviral therapy selection and duration: Immunocompromised patients
         </strong>
         – For immunocompromised patients at high risk for dissemination, we suggest intravenous (IV)
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         (10 mg/kg every eight hours)  (
         <a class="graphic graphic_algorithm graphicRef143355" href="/z/d/graphic/143355.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Examples include hematopoietic cell or organ transplant recipients in the pre- or early post-engraftment period or those with graft-versus-host disease, and patients with cancer and leukopenia. After initial clinical improvement, patients may be switched to an oral agent until all lesions have crusted (typically 7 to 14 days). (See
         <a class="local">
          'Immunocompromised patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For other immunocompromised patients (eg, persons with HIV and CD4 &lt;200 cells/microL, persons receiving chronic corticosteroids or biologic agents for autoimmune conditions), we prefer oral
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         (1000 mg three times daily) or
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          famciclovir
         </a>
         (500 mg three times daily) rather than oral
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         . Transition to IV acyclovir is appropriate if new vesicle formation continues despite several days of oral therapy. (See
         <a class="local">
          'Expected response to treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Limited
         </strong>
         <strong>
          role of adjunctive therapies
         </strong>
         – In patients with uncomplicated zoster, we suggest against the routine use of adjunctive therapies, such as
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         , tricyclic antidepressants, or glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The clinical benefit of these agents in reducing the risk of acute neuritis has not been clearly demonstrated and there are significant risks associated with these medications. (See
         <a class="local">
          'Limited role for adjunctive therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acute pain management (acute neuritis)
         </strong>
         – Pain associated with herpes zoster can be severe, and may require specific interventions in addition to antiviral therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For all patients with acute pain, we offer nonsteroidal anti-inflammatory drugs and/or
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For those with severe pain, additional agents may be needed; the choice of agent depends in part on patient comorbidities and preferences. (See
         <a class="local">
          'Management of acute neuritis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Opioid analgesics
         </strong>
         – Short-acting opioid analgesics (eg,
         <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">
          oxycodone
         </a>
         ) are often the first option because of their efficacy in managing severe acute pain and evidence supporting their use in acute zoster neuritis. We use the lowest effective dose for the shortest duration possible because of associated side effects, especially in older patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Corticosteroids
         </strong>
         – If the patient has severe pain despite a short-acting opioid, a short course of corticosteroids may offer some benefit (eg, 10- to 14-day tapering course of oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         starting at 40 mg/day). Limited data suggest the addition of corticosteroids to
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         may improve overall well-being and/or improve acute pain. However, we try to avoid corticosteroids in those with certain comorbid conditions (eg, diabetes mellitus).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Other agents
         </strong>
         – If short-acting opioids and/or corticosteroids are unsuccessful, we offer treatments that are used for the management of postherpetic neuralgia (eg,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary bacterial infections
         </strong>
         – If a secondary bacterial infection occurs, patients should receive an antibiotic regimen that includes coverage for both staphylococcal and streptococcal species. (See
         <a class="local">
          'Secondary bacterial infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of complicated disease
         </strong>
         – Patients with herpes zoster can present with disseminated infection and/or localized ocular, otic, or neurologic manifestations. (See
         <a class="local">
          'Complicated zoster'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some patients may require IV therapy. As an example, in patients with disseminated infection, we suggest initial treatment with IV
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         rather than oral therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Disseminated infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We also administer adjunctive therapies in certain settings. As an example, in patients with Ramsay Hunt syndrome, we suggest adjunctive glucocorticoids in addition to antiviral therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Ramsay Hunt syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with ocular disease (eg, herpes zoster ophthalmicus, acute retinal necrosis) should be managed in conjunction with an ophthalmologist. Immediate treatment is required since these conditions can be associated with loss of vision. (See
         <a class="local">
          'Ocular disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preventing transmission to others
         </strong>
         – For patients with dermatomal zoster, varicella-zoster virus (VZV) is transmitted by direct contact or by aerosolization of virus from skin lesions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         To reduce the risk of transmitting VZV to others, patients should keep the rash covered until all lesions have crusted. (See
         <a class="local">
          'Preventing transmission to others'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         They should also avoid contact with individuals who may be at risk for acquiring VZV. This includes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         All immunocompromised individuals
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immunocompetent individuals who have neither had varicella (chickenpox) nor received the
         <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">
          varicella vaccine
         </a>
        </p>
        <p>
        </p>
        <p>
         Additional precautions are needed for those with disseminated disease. (See
         <a class="medical medical_review" href="/z/d/html/4047.html" rel="external">
          "Prevention and control of varicella-zoster virus in hospitals"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 Suppl 1:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood MJ, Kay R, Dworkin RH, et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med 1997; 157:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scand J Infect Dis Suppl 1991; 80:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009; :CD006866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995; 123:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller GG, Dummer JS. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am J Transplant 2007; 7:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKay SL, Guo A, Pergam SA, Dooling K. Herpes Zoster Risk in Immunocompromised Adults in the United States: A Systematic Review. Clin Infect Dis 2020; 71:e125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. Ann Intern Med 1999; 130:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shafran SD, Tyring SK, Ashton R, et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004; 29:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000; 9:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pott Junior H, de Oliveira MFB, Gambero S, Amazonas RB. Randomized clinical trial of famciclovir or acyclovir for the treatment of herpes zoster in adults. Int J Infect Dis 2018; 72:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39:1546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gnann JW Jr. New antivirals with activity against varicella-zoster virus. Ann Neurol 1994; 35 Suppl:S69.
          </a>
         </li>
         <li class="breakAll">
          Balfour HH, Jr., Bean B, Laskin OL, Ambinder RF, Meyers JD, Wade JC, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. The New England journal of medicine. 1983; 308:1448. Epub 1983/06/16.
         </li>
         <li class="breakAll">
          Whitley RJ, Gnann JW, Jr., Hinthorn D, Liu C, Pollard RB, Hayden F, et al. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. The Journal of infectious diseases. 1992; 165:450. Epub 1992/03/11.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shepp DH, Dandliker PS, Meyers JD. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N Engl J Med 1986; 314:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serota FT, Starr SE, Bryan CK, et al. Acyclovir treatment of herpes zoster infections. Use in children undergoing bone marrow transplantation. JAMA 1982; 247:2132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyers JD, Wade JC, Shepp DH, Newton B. Acyclovir treatment of varicella-zoster virus infection in the compromised host. Transplantation 1984; 37:571.
          </a>
         </li>
         <li class="breakAll">
          Arora A, Mendoza N, Brantley J, Yates B, Dix L, Tyring S. Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older. The Journal of infectious diseases. 2008; 197:1289. Epub 2008/04/22.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dworkin RH, Barbano RL, Tyring SK, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain 2009; 142:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996; 125:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2008; :CD005582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330:896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esmann V, Geil JP, Kroon S, et al. Prednisolone does not prevent post-herpetic neuralgia. Lancet 1987; 2:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benoldi D, Mirizzi S, Zucchi A, Allegra F. Prevention of post-herpetic neuralgia. Evaluation of treatment with oral prednisone, oral acyclovir, and radiotherapy. Int J Dermatol 1991; 30:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med 2014; 371:1526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmader K. Herpes Zoster. Ann Intern Med 2018; 169:ITC19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santee JA. Corticosteroids for herpes zoster: what do they accomplish? Am J Clin Dermatol 2002; 3:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peng L, Du B, Sun L, et al. Short-term efficacy and safety of prednisone in herpes zoster and the effects on IL-6 and IL-10. Exp Ther Med 2019; 18:2893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry JD, Petersen KL. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology 2005; 65:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanodia SK, Seth AK, Dixit AM. Dose related efficacy of gabapentin in acute herpetic neuralgia among geriatric patients. Indian J Dermatol 2012; 57:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bulilete O, Leiva A, Rullán M, et al. Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: A double blind, randomized controlled trial. PLoS One 2019; 14:e0217335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee EG, Lee HJ, Hyun DJ, et al. Efficacy of low dose gabapentin in acute herpes zoster for preventing postherpetic neuralgia: a prospective controlled study. Dermatol Ther 2016; 29:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lapolla W, Digiorgio C, Haitz K, et al. Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. Arch Dermatol 2011; 147:901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Wijck AJ, Opstelten W, Moons KG, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet 2006; 367:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hope-Simpson Re. The Nature of Herpes Zoster: A Long-term studty and a New Hypothesis. Proc R Soc Med 1965; 58:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tseng HF, Chi M, Smith N, et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis 2012; 206:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yawn BP, Wollan PC, Kurland MJ, et al. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 2011; 86:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balfour HH Jr, Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983; 308:1448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoenberger SD, Kim SJ, Thorne JE, et al. Diagnosis and Treatment of Acute Retinal Necrosis: A Report by the American Academy of Ophthalmology. Ophthalmology 2017; 124:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durand ML, Barshak MB, Chodosh J. Infectious Keratitis in 2021. JAMA 2021; 326:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uscategui T, Dorée C, Chamberlain IJ, Burton MJ. Antiviral therapy for Ramsay Hunt syndrome (herpes zoster oticus with facial palsy) in adults. Cochrane Database Syst Rev 2008; :CD006851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coulson S, Croxson GR, Adams R, Oey V. Prognostic factors in herpes zoster oticus (ramsay hunt syndrome). Otol Neurotol 2011; 32:1025.
          </a>
         </li>
         <li class="breakAll">
          http://www.cdc.gov/shingles/about/transmission.html (Accessed on June 28, 2012).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8293 Version 37.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12151472" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clinical practice. Herpes zoster.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17143845" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Recommendations for the management of herpes zoster.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8838194" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9129551" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1803501" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Zoster-associated chronic pain: an overview of clinical trials with acyclovir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19370655" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Antiviral treatment for preventing postherpetic neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7778840" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17391119" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Herpes simplex and varicella zoster viruses: forgotten but not gone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31677266" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Herpes Zoster Risk in Immunocompromised Adults in the United States: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10375341" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Recent advances in varicella-zoster virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15018852" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11031393" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29746903" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Randomized clinical trial of famciclovir or acyclovir for the treatment of herpes zoster in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7492102" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8185303" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : New antivirals with activity against varicella-zoster virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8185303" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : New antivirals with activity against varicella-zoster virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8185303" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : New antivirals with activity against varicella-zoster virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3001523" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7038177" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Acyclovir treatment of herpes zoster infections. Use in children undergoing bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6328703" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Acyclovir treatment of varicella-zoster virus infection in the compromised host.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6328703" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Acyclovir treatment of varicella-zoster virus infection in the compromised host.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19195785" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8702088" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18254083" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Corticosteroids for preventing postherpetic neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8114860" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2885599" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Prednisolone does not prevent post-herpetic neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2050460" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Prevention of post-herpetic neuralgia. Evaluation of treatment with oral prednisone, oral acyclovir, and radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25317872" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Clinical practice. Postherpetic neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30083718" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Herpes Zoster.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12358552" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Corticosteroids for herpes zoster: what do they accomplish?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31572533" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Short-term efficacy and safety of prednisone in herpes zoster and the effects on IL-6 and IL-10.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16087911" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23112355" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Dose related efficacy of gabapentin in acute herpetic neuralgia among geriatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31166976" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: A double blind, randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26799145" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Efficacy of low dose gabapentin in acute herpes zoster for preventing postherpetic neuralgia: a prospective controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21482862" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16427490" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14267505" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The Nature of Herpes Zoster: A Long-term studty and a New Hypothesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22669900" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21220354" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Herpes zoster recurrences more frequent than previously reported.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6343861" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Acyclovir halts progression of herpes zoster in immunocompromised patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28094044" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Diagnosis and Treatment of Acute Retinal Necrosis: A Report by the American Academy of Ophthalmology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34609465" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Infectious Keratitis in 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18843734" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Antiviral therapy for Ramsay Hunt syndrome (herpes zoster oticus with facial palsy) in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21725270" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Prognostic factors in herpes zoster oticus (ramsay hunt syndrome).
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
